Market Overview

Credit Suisse: Celgene Needs To Win Back Investor Trust

Credit Suisse: Celgene Needs To Win Back Investor Trust
Related CELG
4 Biotech Pipeline Areas To Keep An Eye On In 2019
5 Top-Selling Drugs With Growth Potential In 2019
The Week That Was In San Francisco: 2019 Should Be A Great Year For Healthcare Stocks (Seeking Alpha)

Bulls have emerged in defense of Celgene Corporation (NASDAQ: CELG) as the sell-off continues after unfavorable news from the U.S. Food and Drug Administration.

Both William Blair and Credit Suisse advised investors to keep buying.

The Rating

Credit Suisse analyst Alethia Young reiterated an Outperform rating on Celgene but lowered the price target from $130 to $129.

The Thesis

The FDA rejected Celgene’s New Drug Application for ozanimod in the treatment of relapsing multiple sclerosis.

“Overall, we think this update is another unexpected hiccup after a six-month period that came with many unexpected setbacks, and so we think shares may trade down 5 to 10 percent based on the additional setback and execution questions,” Young said in a Tuesday note. (See the analyst's track record here.) 

Renewed trust in Celgene management is critical to the investment thesis, Young said. 

The analyst previously modeled for 2019 ozanimod sales between $250 million and $500 million, but lowered to zero to $135 million on the news.

“We continue to think Celgene has many viable pipeline assets and a base business that is still growing meaningfully, but execution and Revlimid IP remain key risks." 

Price Action

At the time of publication, shares were trading down 7.9 percent at $88.22. 

Related Links:

Celgene's Pipeline In Question After GED Failure

A Survey Of Celgene's M&A Strategy

Latest Ratings for CELG

Jan 2019BairdUpgradesNeutralOutperform
Jan 2019Wells FargoMaintainsMarket PerformMarket Perform
Jan 2019Goldman SachsUpgradesSellNeutral

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Alethia Young Credit SuisseAnalyst Color Biotech Price Target Reiteration Analyst Ratings General Best of Benzinga


Related Articles (CELG)

View Comments and Join the Discussion!

Latest Ratings

CNPRBC CapitalUpgrades34.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Bill Ackman Exits Herbalife, Builds New Stake In United Technologies

Cramer: Macy's Is Run By A 'Miracle Worker'